- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Myrbetriq, Myrbetriq
Synonyms :
mirabegron
Class :
Beta 3 adrenergic agonists
Dosage Forms & Strengths
Extended-release tablet
25mg
50mg
Monotherapy:
25 - 50
mg
Orally
every day
Tablet
Combined with muscarinic agonist
25mg orally everyday combined with 5mg every day solifenacin succinate, up to 50mg orally every day after 4-8 weeks
Dosage Forms & Strengths
Extended-release tablet
25mg
50mg
neurogenic detrusor overactivity
<3 years: Safety and efficacy not established
≥3 years: Weight <35kg
Oral suspension granules
11kg to <22kg: 24mg orally every day, initially up to 48mg/day
22 to <35kg: 32mg orally every day, initially up to 64mg/day
≥3 years: Weight >35kg
25mg orally every day up to 50mg orally
Oral suspension granules: 48mg orally every day, initially up to 80mg/day
Refer adult dosing
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mirabegron
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may enhance the hypoglycemic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
It may enhance the metabolism when combined with dexamethasone
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may reduce the antihypertensive effect
may reduce the antihypertensive effect
may reduce the antihypertensive effect
may reduce the antihypertensive effect
may reduce the antihypertensive effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may increase the AV-blocking effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may increase the adverse effect of Anticholinergic Agents
Frequency defined:
>10%
Urinary tract infection
Elevated BP
1-10%
Children
Cough
Nausea
Rhinitis
Constipation
Headache
Nasopharyngitis
Gastroenteritis
Adults
Monotherapy
Arthralgia
Headache
Dizziness
Diarrhea
Fatigue
Constipation
Dry mouth
Sinusitis
Urinary tract infection
Combined with solifenacin
Arthralgia
Dizziness
Constipation
Dry mouth
Dyspepsia
Blurred vision
UTI
Tachycardia
<1%
Rhinitis
Glaucoma
Palpitation
Bladder pain
Urticaria
Lip edema
Rash
Elevated blood pressure
Gastritis
Post-marketing reports
Constipation
Nausea
Atrial fibrillation
Angioedema
Dizziness
Urinary retention
pruritus
Pregnancy consideration: Insufficient data available
Lactation: The excretion of the drug is unknown
Pregnancy category:
Patient information leaflet
Generic Name: mirabegron
Pronounced: mye-ra-beg-ron
Why do we use mirabegron?
It is used to treat neurogenic detrusor overactivity and overactive bladder
ADVERTISEMENT
